Ståle Nygård is a researcher at the Section for molecular epidemiology and infections.
He completed his Ph.D. in statistics at the University of Oslo in 2008.
He joined the Cancer Registry in October 2020. His research focuses on HPV-related cancer.
A main topic of his research the effect of HPV vaccines against cervical cancer and pre-cancer as well as other HPV-induced illnesses.
He is also involved in projects looking into age-dependent oncogenicity of HPV-types, natural history of HPV and head and neck cancer, methylation as a biomarker for HPV-related cancers, and machine learning applied to big data for improved cancer/pre-cancer prediction.
Ståle Nygård is a researcher at the Section for molecular epidemiology and infections
He completed his Ph.D. in statistics at the University of Oslo in 2008. He has worked at the Center for Bioinformatics, UiO, with a primary focus on the analysis of genomic data.
Ståle Nygård joined the Cancer Registry in October 2020. His research focuses on HPV-related cancer.
A main topic of his research is the effect of HPV vaccines against cervical cancer, pre-cancer, genital warts and recurrent respiratory papillomatosis.
Currently he is involved in a project where cervical cancer and pre-cancer development is predicted by HPV-type and age. He is also interested in how the HPV-type distribution is affected by vaccination and the implication for HPV-based screening.
He is interested in the association between HPV and head and neck cancer. In particular, he will be exploring the time from HPV infection to head and neck cancer incidence.
He is involved in a project evaluating methylation as biomarker for cancer and pre-cancer development.
Finally, he is looking into machine learning approaches to improve on cervical cancer and pre-cancer prediction using survey data assembled with health registry data.
He is deputy representative for the Norwegian Association of Researchers (Forskerforbundet) at the Cancer Registry.
Publications:
Nygård S, Nygård M, Orumaa M, Hansen BT. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals. Vaccine. 2023 Aug 23;41(37):5469-5476. doi: 10.1016/j.vaccine.2023.07.031. Epub 2023 Jul 27. Erratum in: Vaccine. 2023 Aug 26;: PMID: 37516572.
Pastorino R, Sassano M, Danilo Tiziano F, Giraldi L, Amore R, Arzani D, Abiusi E, Ahrens W, Vilches LA, Canova C, Healy CM, Holcatova I, Lagiou P, Polesel J, Popovic M, Nygård S, Cadoni G, Znaor A, Boffetta P, Matsuo K, Oze I, Brennan P, Boccia S. Plasma miR-151-3p as a Candidate Diagnostic Biomarker for Head and Neck Cancer: A Cross-sectional Study within the INHANCE Consortium. Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2237-2243. doi: 10.1158/1055-9965.EPI-22-0376. PMID: 36126276; PMCID: PMC9720423.
Nygård M, Nygård S. The Future of Cervical Cancer Prevention: From "One-Size-Fits-All" to Personalized Screening. J Pers Med. 2023 Jan 17;13(2):161. doi: 10.3390/jpm13020161. PMID: 36836396; PMCID: PMC9966965.
Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD. PathTracer: High-sensitivity detection of differential pathway activity in tumours. Sci Rep. 2019 Nov 8;9(1):16332. doi: 10.1038/s41598-019-52529-3. PMID: 31704995; PMCID: PMC6841931.
Media:
Skal vi screene og konisere inn i evigheten eller bytte hpv-vaksine? - Dagens medisin 2023
White paper: Raskere eliminering av livmorhalskreft - Kreftregisteret.no 2023
HPV-vaksinen må bli invitert til voksenfesten - Aftenposten 2023
Jo, vi kan utrydde HPV og livmorhalskreft raskere - Aftenposten 2023
Hvor fort vi eliminerer livmorhalskreft i Norge, er et valg - Altså 2023
